All Articles

Lykos Therapeutics Launches With $100 Million For MDMA Treatments

January 7, 2024
x min read

The most important non profit organization in the history of psychedelics has just launched their first ever for profit biotechnology company.

What’s happening:

  • The Multidisciplinary Association for Psychedelic Studies, most commonly referred to as MAPS, has officially launched Lykos Therapeutics as a for profit biotechnology company to advance MDMA assisted therapies
  • Lykos Therapeutics, which was formerly known as MAPS Public Benefit Corporation and previously wholly owned by MAPS, has raised $100M USD in a Series A round led by Helena, with participation from billionaire Steve Cohen’s family foundation, True Ventures and Satori Neuro

Why it matters:

  • For decades, MAPS has been leading the psychedelic renaissance through their scientific research and advocacy efforts to attempt to make psychedelic compounds accessible to patients
  • MAPS Public Benefit Corporation has been the longstanding leader in psychedelic science through their groundbreaking Phase III clinical trial of MDMA for the treatment of Post Traumatic Stress Disorder
  • Launching Lykos Therapeutics as a for profit biotechnology company marks a potentially pivotal turning point for the future of MDMA assisted therapies being able to be commercialized in the near future

Going deeper:

  • The majority of the new funding in Lykos Therapeutics will go towards preparing to commercialize MDMA assisted therapies, pending an official approval from the FDA
  • MAPS will still continue to maintain oversight of Lykos Therapeutics through having significant control of the voting power within the company

The intrigue:

  • Helena, the lead investor in this round, is a global problem solving organization which includes many notable members, such as Citadel’s Ken Griffin, Snapchat’s Evan Spiegel and legendary billionaire energy trader John Arnold

Discover what’s next. The world’s biggest ideas, disruptive trends, most exciting early stage companies and groundbreaking entrepreneurs.

By clicking Subscribe you're confirming that you agree with our Privacy Policy.
Thanks for subscribing!
Keep an eye out for a welcome email shortly.
Oops! Something went wrong while submitting the form.